Experimental Treatment Combination Shows Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
source: pixabay.com

Experimental Treatment Combination Shows Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

  Researchers acknowledge that the primary cause of failure of stem cell transplants is disease relapse. This holds true specifically for allogeneic hematopoietic stem cell transplants where a cancer patient…

Continue Reading Experimental Treatment Combination Shows Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
FDA Orphan Drug Designation for AML and Pancreatic Cancer Treatment Possibly More Effective Than Chemotherapy
source: pixabay.com

FDA Orphan Drug Designation for AML and Pancreatic Cancer Treatment Possibly More Effective Than Chemotherapy

The FDA has just provided AB001 the Orphan Drug designation for both acute myeloid leukemia (AML) and pancreatic cancer. This small molecule was developed by Vopec Pharmaceuticals and Agastiya Biotech.…

Continue Reading FDA Orphan Drug Designation for AML and Pancreatic Cancer Treatment Possibly More Effective Than Chemotherapy

FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy

Karyopharm Therapeutics has just announced that Eltanexor, their investigative therapy for myelodysplastic syndromes (MDS), has been given Orphan Drug Designation by the FDA. This designation means that the FDA believes…

Continue Reading FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy
Recent Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
https://unsplash.com/photos/8rj4sz9YLCI

Recent Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes

An article in PubMed dated October 8, 2021 outlines immune therapies treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients. Both cancers are hematologic malignancies that begin in the…

Continue Reading Recent Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Dr. Richard Stone Discusses Development of Eight Drugs for Acute Myeloid Leukemia Within Four Years
source: pixabay.com

Dr. Richard Stone Discusses Development of Eight Drugs for Acute Myeloid Leukemia Within Four Years

  Dr. Richard Stone recently interviewed with Targeted Oncology to discuss challenging acute myeloid leukemia subtypes and a list of available therapies. Dr. Stone was asked to look back at…

Continue Reading Dr. Richard Stone Discusses Development of Eight Drugs for Acute Myeloid Leukemia Within Four Years
A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer
source: pixabay.com

A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer

Breast cancer is a result of a cell in the breast mutating and multiplying rapidly. There are over 275,000 occurrences of breast cancer in the U.S. each year. However, new…

Continue Reading A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer
Acute Myeloid Leukemia (AML): The Fine Line Between Proliferation of AML Cells and Death Of AML Cells
source: pixabay.com

Acute Myeloid Leukemia (AML): The Fine Line Between Proliferation of AML Cells and Death Of AML Cells

According to a recent article in MedicalXpress, researchers led by professor of medicine Dr. Jing Chen uncovered new data showing how acute myeloid leukemia (AML) becomes active and progresses. The…

Continue Reading Acute Myeloid Leukemia (AML): The Fine Line Between Proliferation of AML Cells and Death Of AML Cells
Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
PhotoLizM / Pixabay

Phase 3 Data Available on Pevonedistat for AML, MDS, CMML

In the Phase 3 PANTHER clinical trial, also known as the Pevonedistat-3001 study, researchers were evaluating pevonedistat in conjunction with azacitidine for patients with acute myeloid leukemia (AML), myelodysplastic syndromes…

Continue Reading Phase 3 Data Available on Pevonedistat for AML, MDS, CMML